The use of next-generation sequencing in molecular diagnosis of neurofibromatosis type 1

a validation study

Ryo Maruoka, Toshiki Takenouchi, Chiharu Torii, Atsushi Shimizu, Kumiko Misu, Koichiro Higasa, Fumihiko Matsuda, Arihito Ota, Katsumi Tanito, Akira Kuramochi, Yoshimi Arima, Fujio Otsuka, Yuichi Yoshida, Keiji Moriyama, Michihito Niimura, Hideyuki Saya, Kenjiro Kosaki

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

AIMS: We assessed the validity of a next-generation sequencing protocol using in-solution hybridization-based enrichment to identify NF1 mutations for the diagnosis of 86 patients with a prototypic genetic syndrome, neurofibromatosis type 1. In addition, other causative genes for classic genetic syndromes were set as the target genes for coverage analysis.

RESULTS: The protocol identified 30 nonsense, 19 frameshift, and 8 splice-site mutations, together with 10 nucleotide substitutions that were previously reported to be pathogenic. In the remaining 19 samples, 10 had single-exon or multiple-exon deletions detected by a multiplex ligation-dependent probe amplification method and 3 had missense mutations that were not observed in the normal Japanese SNP database and were predicted to be pathogenic. Coverage analysis of the genes other than the NF1 gene included on the same diagnostic panel indicated that the mean coverage was 115-fold, a sufficient depth for mutation detection.

CONCLUSIONS: The overall mutation detection rate using the currently reported method in 86 patients who met the clinical diagnostic criteria was 92.1% (70/76) when 10 patients with large deletions were excluded. The results validate the clinical utility of this next-generation sequencing-based method for the diagnosis of neurofibromatosis type 1. Comparable detection rates can be expected for other genetic syndromes, based on the results of the coverage analysis.

Original languageEnglish
Pages (from-to)722-735
Number of pages14
JournalGenetic Testing and Molecular Biomarkers
Volume18
Issue number11
DOIs
Publication statusPublished - 2014 Nov 1

Fingerprint

Neurofibromatosis 1
Validation Studies
Mutation
Genes
Exons
Multiplex Polymerase Chain Reaction
Mutation Rate
Missense Mutation
Single Nucleotide Polymorphism
Nucleotides
Databases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The use of next-generation sequencing in molecular diagnosis of neurofibromatosis type 1 : a validation study. / Maruoka, Ryo; Takenouchi, Toshiki; Torii, Chiharu; Shimizu, Atsushi; Misu, Kumiko; Higasa, Koichiro; Matsuda, Fumihiko; Ota, Arihito; Tanito, Katsumi; Kuramochi, Akira; Arima, Yoshimi; Otsuka, Fujio; Yoshida, Yuichi; Moriyama, Keiji; Niimura, Michihito; Saya, Hideyuki; Kosaki, Kenjiro.

In: Genetic Testing and Molecular Biomarkers, Vol. 18, No. 11, 01.11.2014, p. 722-735.

Research output: Contribution to journalArticle

Maruoka, R, Takenouchi, T, Torii, C, Shimizu, A, Misu, K, Higasa, K, Matsuda, F, Ota, A, Tanito, K, Kuramochi, A, Arima, Y, Otsuka, F, Yoshida, Y, Moriyama, K, Niimura, M, Saya, H & Kosaki, K 2014, 'The use of next-generation sequencing in molecular diagnosis of neurofibromatosis type 1: a validation study', Genetic Testing and Molecular Biomarkers, vol. 18, no. 11, pp. 722-735. https://doi.org/10.1089/gtmb.2014.0109
Maruoka, Ryo ; Takenouchi, Toshiki ; Torii, Chiharu ; Shimizu, Atsushi ; Misu, Kumiko ; Higasa, Koichiro ; Matsuda, Fumihiko ; Ota, Arihito ; Tanito, Katsumi ; Kuramochi, Akira ; Arima, Yoshimi ; Otsuka, Fujio ; Yoshida, Yuichi ; Moriyama, Keiji ; Niimura, Michihito ; Saya, Hideyuki ; Kosaki, Kenjiro. / The use of next-generation sequencing in molecular diagnosis of neurofibromatosis type 1 : a validation study. In: Genetic Testing and Molecular Biomarkers. 2014 ; Vol. 18, No. 11. pp. 722-735.
@article{5473250424584cc1bda2a6a589c8c370,
title = "The use of next-generation sequencing in molecular diagnosis of neurofibromatosis type 1: a validation study",
abstract = "AIMS: We assessed the validity of a next-generation sequencing protocol using in-solution hybridization-based enrichment to identify NF1 mutations for the diagnosis of 86 patients with a prototypic genetic syndrome, neurofibromatosis type 1. In addition, other causative genes for classic genetic syndromes were set as the target genes for coverage analysis.RESULTS: The protocol identified 30 nonsense, 19 frameshift, and 8 splice-site mutations, together with 10 nucleotide substitutions that were previously reported to be pathogenic. In the remaining 19 samples, 10 had single-exon or multiple-exon deletions detected by a multiplex ligation-dependent probe amplification method and 3 had missense mutations that were not observed in the normal Japanese SNP database and were predicted to be pathogenic. Coverage analysis of the genes other than the NF1 gene included on the same diagnostic panel indicated that the mean coverage was 115-fold, a sufficient depth for mutation detection.CONCLUSIONS: The overall mutation detection rate using the currently reported method in 86 patients who met the clinical diagnostic criteria was 92.1{\%} (70/76) when 10 patients with large deletions were excluded. The results validate the clinical utility of this next-generation sequencing-based method for the diagnosis of neurofibromatosis type 1. Comparable detection rates can be expected for other genetic syndromes, based on the results of the coverage analysis.",
author = "Ryo Maruoka and Toshiki Takenouchi and Chiharu Torii and Atsushi Shimizu and Kumiko Misu and Koichiro Higasa and Fumihiko Matsuda and Arihito Ota and Katsumi Tanito and Akira Kuramochi and Yoshimi Arima and Fujio Otsuka and Yuichi Yoshida and Keiji Moriyama and Michihito Niimura and Hideyuki Saya and Kenjiro Kosaki",
year = "2014",
month = "11",
day = "1",
doi = "10.1089/gtmb.2014.0109",
language = "English",
volume = "18",
pages = "722--735",
journal = "Genetic Testing and Molecular Biomarkers",
issn = "1945-0265",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - The use of next-generation sequencing in molecular diagnosis of neurofibromatosis type 1

T2 - a validation study

AU - Maruoka, Ryo

AU - Takenouchi, Toshiki

AU - Torii, Chiharu

AU - Shimizu, Atsushi

AU - Misu, Kumiko

AU - Higasa, Koichiro

AU - Matsuda, Fumihiko

AU - Ota, Arihito

AU - Tanito, Katsumi

AU - Kuramochi, Akira

AU - Arima, Yoshimi

AU - Otsuka, Fujio

AU - Yoshida, Yuichi

AU - Moriyama, Keiji

AU - Niimura, Michihito

AU - Saya, Hideyuki

AU - Kosaki, Kenjiro

PY - 2014/11/1

Y1 - 2014/11/1

N2 - AIMS: We assessed the validity of a next-generation sequencing protocol using in-solution hybridization-based enrichment to identify NF1 mutations for the diagnosis of 86 patients with a prototypic genetic syndrome, neurofibromatosis type 1. In addition, other causative genes for classic genetic syndromes were set as the target genes for coverage analysis.RESULTS: The protocol identified 30 nonsense, 19 frameshift, and 8 splice-site mutations, together with 10 nucleotide substitutions that were previously reported to be pathogenic. In the remaining 19 samples, 10 had single-exon or multiple-exon deletions detected by a multiplex ligation-dependent probe amplification method and 3 had missense mutations that were not observed in the normal Japanese SNP database and were predicted to be pathogenic. Coverage analysis of the genes other than the NF1 gene included on the same diagnostic panel indicated that the mean coverage was 115-fold, a sufficient depth for mutation detection.CONCLUSIONS: The overall mutation detection rate using the currently reported method in 86 patients who met the clinical diagnostic criteria was 92.1% (70/76) when 10 patients with large deletions were excluded. The results validate the clinical utility of this next-generation sequencing-based method for the diagnosis of neurofibromatosis type 1. Comparable detection rates can be expected for other genetic syndromes, based on the results of the coverage analysis.

AB - AIMS: We assessed the validity of a next-generation sequencing protocol using in-solution hybridization-based enrichment to identify NF1 mutations for the diagnosis of 86 patients with a prototypic genetic syndrome, neurofibromatosis type 1. In addition, other causative genes for classic genetic syndromes were set as the target genes for coverage analysis.RESULTS: The protocol identified 30 nonsense, 19 frameshift, and 8 splice-site mutations, together with 10 nucleotide substitutions that were previously reported to be pathogenic. In the remaining 19 samples, 10 had single-exon or multiple-exon deletions detected by a multiplex ligation-dependent probe amplification method and 3 had missense mutations that were not observed in the normal Japanese SNP database and were predicted to be pathogenic. Coverage analysis of the genes other than the NF1 gene included on the same diagnostic panel indicated that the mean coverage was 115-fold, a sufficient depth for mutation detection.CONCLUSIONS: The overall mutation detection rate using the currently reported method in 86 patients who met the clinical diagnostic criteria was 92.1% (70/76) when 10 patients with large deletions were excluded. The results validate the clinical utility of this next-generation sequencing-based method for the diagnosis of neurofibromatosis type 1. Comparable detection rates can be expected for other genetic syndromes, based on the results of the coverage analysis.

UR - http://www.scopus.com/inward/record.url?scp=84933518597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933518597&partnerID=8YFLogxK

U2 - 10.1089/gtmb.2014.0109

DO - 10.1089/gtmb.2014.0109

M3 - Article

VL - 18

SP - 722

EP - 735

JO - Genetic Testing and Molecular Biomarkers

JF - Genetic Testing and Molecular Biomarkers

SN - 1945-0265

IS - 11

ER -